This evidence, on one hand, indicates that the selective removal of CD133+ or EpCAM+ cells may not be sufficient to eradicate cells with the most aggressive phenotype, like cancer stem cells, and on the other hand that the simultaneous targeting of the two surface antigens may be of clinical relevance in treatment of TNBC patients. Here, EPCAM is linked to cancer.